论文部分内容阅读
目的 探讨组织蛋白酶D(Cathepsin ,CD)和P选择素 (Pseleltin ,Ps)在非小细胞肺癌 (NSCLC)中的表达及其临床意义。方法 应用免疫组织化学技术 (SP法 )检测 3 0例NSCLC石蜡切片组织中CD和Ps的表达。结果 CD和Ps的阳性率分别为 66 7%( 2 0 / 3 0 )、76 7%( 2 3 / 3 0 )。CD表达与肿块大小、病理分期及淋巴结转移呈正相关 (P <0 0 5 ) ,与 3年存活率呈负相关 (P <0 0 5 ) ,与患者年龄、性别、分化程度、病理类型无显著相关 (P >0 0 5 )。Ps表达则与患者年龄、性别、分化程度、肿块大小、病理类型、病理分期及 3年存活率均无关 (P >0 0 5 )。二者均阳性的患者 3年存活率为 2 5 0 %( 4 / 16) ,明显低于同时阴性者的 10 0 %( 3 / 3 ) (P <0 0 5 )。结论 CD可作为NSCLC淋巴结转移的重要标志 ,是高危预后指标。CD和Ps联合检测 ,可更精确地判断预后 ,为制定治疗方案提供依据
Objective To investigate the expression of cathepsin D (CD) and Pseleltin (Ps) in non-small cell lung cancer (NSCLC) and its clinical significance. Methods Immunohistochemistry (SP method) was used to detect the expression of CD and Ps in 30 NSCLC paraffin sections. Results The positive rates of CD and Ps were 66 7% (20/30) and 76 7% (23/30), respectively. The expression of CD was positively correlated with tumor size, pathological stage and lymph node metastasis (P <0.05), but negatively correlated with 3-year survival rate (P <0.05), but not with age, gender, differentiation and pathological type Related (P> 0 0 5). There was no correlation between the expression of Ps and age, gender, differentiation, tumor size, pathological type, pathological stage and 3-year survival rate (P> 0.05). The 3-year survival rate was 25.0% (4/16) in patients who were both positive, which was significantly lower than that in the negative patients at 10 0% (3/3) (P 0 05). Conclusion CD can be used as an important marker of lymph node metastasis in NSCLC and is a high risk prognostic indicator. CD and Ps joint detection, can more accurately determine the prognosis, to provide a basis for the development of treatment options